Detecting Cancer Before It Starts: How One Arizona Startup Is Transforming Precision Oncology
In modern medicine, early cancer detection remains a central goal. Identifying a tumor before symptoms emerge often makes the difference between routine intervention and a terminal diagnosis.
Standing at the leading edge of this shift is Precision Epigenomics, a Tucson-based bioscience startup whose rapid trajectory over the past 18 months is drawing national attention. Through cutting-edge liquid biopsy technology, rigorous laboratory standards, and high-impact strategic partnerships, the company is turning complex epigenetic science into life-saving clinical tools.
Science Meets Gold-Standard Precision
At the heart of the company’s diagnostic pipeline is EPISEEK®, an innovative multi-cancer early detection (MCED) blood test. By capturing subtle epigenetic signals from circulating tumor DNA (ctDNA), EPISEEK can detect more than 60 distinct cancer types—including brain cancers—from a single blood draw.
To ensure its diagnostic results are as reliable as they are revolutionary, Precision Epigenomics built its laboratory infrastructure from the ground up in Tucson. That commitment to rigor culminated in a major operational milestone: earning accreditation from the College of American Pathologists (CAP). Considered the gold standard in laboratory quality, CAP accreditation provides clinicians, enterprise health systems, and regulatory partners with absolute confidence in the company’s diagnostic accuracy.
On the Front Lines: Protecting First Responders
While early detection technology holds promise for the general public, it is urgently needed for high-risk populations. Firefighters and law enforcement personnel face chronic exposure to carcinogens on the job, leading to significantly elevated rates of occupational cancer.
In partnership with 1582Exam and HeartFit For Duty, Precision Epigenomics took immediate action in its home state, screening hundreds of Arizona firefighters. Building on that success, the company launched an exclusive partnership with Front Line Mobile Health, a veteran-owned public safety health platform. By integrating the EPISEEK test into routine occupational health exams and department-wide mobile clinics, the initiative is actively expanding into fire departments across Texas, Colorado, and Georgia.
Precision Epigenomics will be honored with an AZBio Fast Lane Award on Oct. 7, 2026 at the Phoenix Convention Center at the 23rd annual AZBio Awards.